ArticleThe Journal of clinical investigation2018

Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.

Yoshikazu Johmura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.